aldesleukin + zoledronic acid

aldesleukin + zoledronic acid is an investigational combination immunotherapy being evaluated for the treatment of multidrug-resistant tuberculosis (MDR-TB). Aldesleukin is a recombinant form of interleukin-2 (IL-2) that promotes the proliferation and activation of T cells and natural killer cells by binding to IL-2 receptors. Zoledronic acid, a nitrogen-containing bisphosphonate, is used in this context to stimulate the expansion of Vγ2Vδ2 T cells by inhibiting farnesyl pyrophosphate synthase, which leads to the accumulation of phosphoantigens like isopentenyl pyrophosphate (IPP). The combination aims to enhance the host's cellular immune response against *Mycobacterium tuberculosis* when used alongside standard chemotherapy. This specific regimen is being studied in an exploratory Phase 4 clinical trial led by the Shanghai Pulmonary Hospital in China.

Other names

Vγ2Vδ2 T lymphocyte-based immunotherapyzoledronic acid/interleukin 2zoledronic acid/interleukin-2